Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

10 recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC) Trials at a Glance

11 actively recruiting trials for head and neck squamous cell carcinoma (hnscc) are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Los Angeles, Pittsburgh, and Manchester. Lead sponsors running head and neck squamous cell carcinoma (hnscc) studies include Sun Yat-sen University, Dana-Farber Cancer Institute, and Dan Zandberg.

Browse head and neck squamous cell carcinoma (hnscc) trials by phase

Treatments under study

About Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

Looking for clinical trials for Head and Neck Squamous Cell Carcinoma (HNSCC)? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Head and Neck Squamous Cell Carcinoma (HNSCC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Head and Neck Squamous Cell Carcinoma (HNSCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Not Applicable

Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University50 enrolled1 locationNCT06630780
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2

Window of Opportunity in Preserving Laryngeal Function Trial

Hypopharyngeal Squamous Cell CarcinomaLocally Advanced Laryngeal Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Matthew Spector87 enrolled1 locationNCT07423078
Recruiting
Phase 2

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute32 enrolled2 locationsNCT07465276
Recruiting
Phase 2

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled2 locationsNCT06769698
Recruiting
Phase 2

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)
Dan Zandberg80 enrolled1 locationNCT04080804
Recruiting
Phase 1Phase 2

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 2Phase 3

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)
Inhibrx Biosciences, Inc410 enrolled88 locationsNCT06295731
Recruiting
Phase 1Phase 2

AK129 Combination Therapy for Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Advanced Solid TumorsColorectal Adenocarcinoma+1 more
Akeso230 enrolled1 locationNCT06943820
Recruiting
Phase 2

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)HNSCC
Sun Yat-sen University24 enrolled2 locationsNCT06673693
Recruiting
Phase 2

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Head and Neck Squamous Cell Carcinoma (HNSCC)Metastatic Head and Neck CancerRecurrent Head and Neck Cancer
Gruppo Oncologico del Nord-Ovest67 enrolled8 locationsNCT06869473